Financial Performance (Standalone)

Q2 FY27 (Quarter Ended September 30, 2026):

  • Revenue: INR 274.6 crores (vs. INR 270.2 crores in Q2 FY26; +1.6% YoY)
  • EBITDA: INR 36.6 crores (vs. INR 30.1 crores in Q2 FY26; +21.5% YoY)
  • EBITDA Margin: 13.3% (vs. 11.1% in Q2 FY26)
  • Profit After Tax (PAT): INR 26.7 crores (vs. INR 18.7 crores in Q2 FY26; +42% YoY)

H1 FY27 (Half Year Ended September 30, 2026):

  • Revenue: INR 568.3 crores (vs. INR 579.7 crores in H1 FY26; -2% YoY)
  • EBITDA: INR 79.0 crores
  • EBITDA Margin: 13.9% (vs. 12.5% in H1 FY26)
  • PAT: INR 55.8 crores
  • PAT Margin: 9.8%

Operational and Strategic Highlights

Business Mix Shift: The company's diversification strategy showed results. For H1 FY27, the revenue mix shifted to 35% from agrochemicals and 65% from non-agro businesses (Performance Solutions, YP derivatives, and Contract Manufacturing). This structural shift helped offset a severe downturn in the traditional agrochemical intermediates business.

DETC Performance: DETC (Diethyl Thiophosphoryl Chloride) sales in Q2 were at their lowest level in the last 7 years (and mentioned as 11 years in the Q&A), primarily due to the Super El Nino effect and a monsoon that was 87% of normal levels, impacting demand in India and LATAM.

Export Growth: Exports increased significantly to INR 81 crores in Q2 FY27 from INR 47 crores in Q2 FY26, driven by the three focus areas: Performance Solutions, YP derivatives, and Contract Manufacturing.

Contract Manufacturing:

  • The dedicated capacity for a 5-year long-term supply arrangement (announced Nov 2025) was successfully commissioned on July 23, 2026, on schedule. Supplies are now at "full stream."
  • Regular supplies under an agreement with a multinational company (announced May 2024) are progressing as per contract.
  • Management indicated the company is on track to achieve its target of approximately INR 15 crores per quarter from its contract manufacturing contracts.

Performance Solutions & YP Derivatives:

  • Additional biocides capacity commissioned in H2 FY26 is fully operational.
  • New product launches are on track: Performance Solutions range in Q3 FY27 and a new YP derivative product in Q4 FY27.
  • The new corporate R&D center (operationalized Q3 FY26) is benefiting product development, with plans to further strengthen its capabilities.

Raw Materials & Inventory:

  • Inventory increased to INR 262 crores in September 2026 from INR 129 crores in March 2026. This build-up was a strategic move due to volatility in raw material prices and availability challenges, aimed at ensuring supply continuity and controlling costs.
  • Management expects raw material price volatility and shipping disruptions to continue creating cost pressure in H2 FY27.

Sustainability & Safety Awards:

  • The company was awarded a silver rating by EcoVadis, placing it in the 93rd percentile globally for sustainability.
  • Received 2 trophies at the Maharashtra Safety Awards 2025 for its Lote site.
  • Roha site received the Safe-Tech Award 2026 for best employee training campaign and safety awareness excellence.
  • Two safety executives were recognized as best safety professionals of the year.

Capital Allocation & Outlook

Capex: The company has a planned capex of INR 200-300 crores over three years. Approximately 50% (around INR 150 crores) has already been committed, focused on the three growth areas (YP derivatives, Performance Solutions, Contract Manufacturing).

Investment Criteria: New investments are guided by a target fixed asset turnover ratio of 1.5 to 2 and a blended Return on Capital Employed (ROCE) target of 15% to 20%, preferably closer to 20%.

Balance Sheet: The company maintains an exceptionally strong net cash position, providing flexibility to navigate challenges and fund growth initiatives from internal accruals.

Outlook: The agrochemical market is expected to remain subdued in the near term, with demand weakness likely persisting in Q3 FY27. The management's focus remains on high-growth potential businesses, operational efficiency, and cost discipline.

Q&A Key Points

Market Share & Competition: Management stated they have not lost market share in DETC despite the downturn. The sharp decline was attributed to poor weather (El Nino) and not competitive pressure.

Anti-Dumping Duty (ADD): The DGTR has recommended anti-dumping duties on HEDP and ATMP. If implemented, management expects an improvement in domestic pricing and margins for these products.

Silox Investment: A shareholder questioned the large investment in Silox India Pvt. Ltd. (estimated market value ~INR 500 cr, dividend yield 2-3%), suggesting its monetization could enhance shareholder value via buybacks or funding more aggressive growth. Management acknowledged the board is aware and reviews the investment but provided no specific timeline or plan for monetization, stating the company's growth plans are not compromised by this holding.

Capacity Utilization: Management noted an improvement in capacity utilization for organophosphonates (following DGTR news) but did not provide specific numbers. For DETC, a full recovery to capacity utilization is expected to take longer due to the company's large capacity relative to competitors.